Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Immutep Announces Japanese Patent Grant for LAG525 Antibody | ||
By: Nasdaq / GlobeNewswire - 17 Sep 2019 | Back to overview list |
|
SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office. The claims of the patent are directed to LAG525, and to the use of LAG525 in the treatment of cancer and infectious disease. LAG525 is a humanised form of Immutep’s IMP701 antibody that was originally developed by Immutep S.A. (now Immutep S.A.S.), a wholly owned subsidiary of the Company. The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 13 March 2035. About IMP701 and LAG525 Rights to the development and commercialisation of IMP701 were licensed to CoStim Pharmaceuticals in 2012, which was subsequently acquired by Novartis in 2014. LAG525, a humanised form of IMP701 is currently being evaluated in five Phase I and/or Phase II clinical trials, in combination with Novartis’ PD-1 inhibitor spartalizumab for the treatment of various cancers. Novartis has full responsibility for the continued development of the antibody program and Immutep is eligible to receive development-based milestone payments and royalties on sales following commercialisation of the antibody. Further information on the clinical studies may be obtained at: https://clinicaltrials.gov/ct2/show/NCT03365791 About Immutep Further information can be found on the Company’s website www.immutep.com or by contacting: U.S. Investors: Australian Investors/Media: U.S. Media: |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |